Overview

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
Phase:
PHASE1
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.